Compare Applied Digital Corporation (APLD) vs AstraZeneca plc (AZN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applied Digital Corporation vs AstraZeneca plc — how do they compare? Applied Digital Corporation trades at $30.81 (market cap $8.90B), while AstraZeneca plc trades at $169.63 (market cap $262.75B). The key difference: AstraZeneca plc is far larger — about 29.5× Applied Digital Corporation's market cap, and AstraZeneca plc pays a 1.84% dividend while Applied Digital Corporation pays none. Which is the better fit depends on your goals.
| APLD | AZN | |
|---|---|---|
Market Cap | $8.90B | $262.75B |
Sector | Technology | Health |
52-Week High | $49.65 | $209.48 |
52-Week Low | $9.18 | $137.44 |
Enterprise Value | $10.00B | $289.00B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Digital (APLD) trades at $31.15, down 3.53% today, amid bearish technical signals despite unanimous analyst buy ratings. The company shows strong revenue growth with $144M in 2025 and $319M projected for 2026, but remains unprofitable with negative margins. Recent news highlights APLD's pivot to AI data centers with $36B in contracted lease value, though execution risks and customer concentration persist.
Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and heavy capital spending. Risks include customer concentration and debt load, but analyst consensus targets $76.67 suggest significant upside if execution improves.
AstraZeneca (AZN) trades at $171.61, down 3.85% following a Phase 3 clinical trial failure for its Wainua heart drug. The stock faces bearish technical signals with support at $167 and resistance at $177. Fundamentally, the company maintains strong profitability with 17.19% net margins and robust revenue growth, reaching $58.74B in 2025. Analyst consensus remains positive with 47.5% buy ratings despite recent setbacks.
The outlook remains cautiously optimistic as AstraZeneca's core business fundamentals remain intact with improving cash flow and debt reduction. However, pipeline execution risks and clinical trial uncertainties present near-term headwinds. Long-term investors may find value at current levels given the company's strong market position and financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Digital Corporation
Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
